Edition:
India

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

16.80USD
16 Feb 2018
Change (% chg)

$0.06 (+0.36%)
Prev Close
$16.74
Open
$16.70
Day's High
$17.32
Day's Low
$16.70
Volume
500,863
Avg. Vol
727,142
52-wk High
$55.28
52-wk Low
$15.29

Select another date:

Thu, Feb 15 2018

BRIEF-Paulson & Co Cuts Share Stake In Mallinckrodt PLC

* PAULSON & CO CUTS SHARE STAKE IN MALLINCKRODT PLC TO 3.7 MILLION SHARES FROM 6.6 MILLION SHARES - SEC FILING

BRIEF-Mallinckrodt Enrolls First Patient In Phase 1 Study Of Skin Tissue

* MALLINCKRODT ENROLLS FIRST PATIENT IN PHASE 1 STUDY OF EXPRESSGRAFT™C9T1 SKIN TISSUE Source text for Eikon: Further company coverage:

BRIEF-Mallinckrodt Says Units Entered A $600 Million Senior Secured Term Loan Facility

* MALLINCKRODT PLC SAYS ON FEB 13, IN CONNECTION WITH THE MERGER, UNITS OF CO ENTERED INTO A $600 MILLION SENIOR SECURED TERM LOAN FACILITY- SEC FILING

BRIEF-First Patient Enrolled In Mallinckrodt Phase 4 Trial Of H.P. Acthar Gel For Pulmonary Sarcoidosis

* FIRST PATIENT ENROLLED IN MALLINCKRODT PHASE 4 TRIAL OF H.P. ACTHAR® GEL (REPOSITORY CORTICOTROPIN INJECTION) FOR PULMONARY SARCOIDOSIS Source text for Eikon: Further company coverage:

BRIEF-Mallinckrodt Will Sell Recothrom, Preveleak To Baxter for $185 Mln

* MALLINCKRODT - TOTAL DEAL CONSIDERATION OF $185 MILLION, WITH $153 MILLION UPFRONT, INCLUDING EXISTING INVENTORY, REMAINDER IN POTENTIAL MILESTONE PAYMENTS

BRIEF-Mallinckrodt Unit Borrowed $900 Mln Under Revolving Credit Facility

* MALLINCKRODT PLC SAYS ON DEC 29 UNIT OF CO BORROWED $900 MILLION AS A REVOLVING LOAN UNDER THE REVOLVING CREDIT FACILITY -SEC FILING

BRIEF-Mallinckrodt Completes Stannsoporfin New Drug Application Filing

* MALLINCKRODT COMPLETES STANNSOPORFIN NEW DRUG APPLICATION FILING Source text for Eikon: Further company coverage:

Mallinckrodt to buy Sucampo for about $840 million

Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc for about $840 million to snap up constipation drug Amitiza and a clutch of experimental rare disease treatments, as it battles declining sales of its biggest drug, Acthar.

UPDATE 2-Mallinckrodt to buy Sucampo for about $840 mln

* Deal for $18/share, a premium of about 6 pct to Friday close

BRIEF-Sucampo Pharma Says If Merger Agreement Terminated, Co Agreed To Pay Mallinckrodt Fee Of $44 Million

* SUCAMPO PHARMACEUTICALS SAYS IF MERGER AGREEMENT TERMINATED UNDER CERTAIN CIRCUMSTANCES, CO AGREED TO PAY MALLINCKRODT FEE OF $44 MILLION - SEC FILING Source text : (http://bit.ly/2BUtNpK) Further company coverage:

Select another date: